팝업레이어 알림

팝업레이어 알림이 없습니다.

Create health, happy lives and beautiful future

EDGC is at the center of the revolution beginning to disappear a border between industries as technologies converge.

  • Help to maintain healthy pregnancy by analyzing fetal chromosomal abnormalities.
  • Detect chromosomal abnormalities a baby may have.
  • Parents can take care of children’s health with proper treatment of analyzing their genes.
  • Analyze the genetic risk of diseases to help prevent them in advance.

Genetic Analysis Service Throughout the Life Cycle

  • What does
    your DNA look like?

    MIT Technology Review paid attention to
    ‘Genetic Fortune Telling’ in ’10 Breakthrough Technologies 2018’.
    Genes have all the information you may wish to know.
    Your genes exactly know your weaknesses, personality, aptitude and even the most effective exercises for you.
    Start to prepare for the era of the healthy 100-year life through genetic analysis.

  • EDGC is
    a global healthcare
    company.

    EDGC analyzes your genes based on
    cutting-edge genetic analysis technology and bioinformatics technology and suggests personalized lifestyle to help prevent diseases.

Business

EDGC Service

  • Non-Invasive Prenatal Test

    NICE®

    NICE® test, which has been verified its accuracy and reliability by acquiring CLIA and CAP certificates, detects fetal chromosomal abnormalities safely and easily.

  • Newborn Genetic Screening Test

    bebegene®

    bebegene® which detects chromosomal abnormalities such as major genetic diseases, Wilson’s Disease, ADHD, hearing loss and so on is the first test for a precious baby.

  • Integrated Genotype and Phenotype Test

    MYGENPLAN®

    MYGENPLAN® is the first integrated test in South Korea which analyzes metabolic genes and biological age and suggests personalized healthcare guide.

  • Cancer and General Disease Prediction Test

    gene2me® Plus

    gene2me® Plus predicts the genetic risk of major cancer, general diseases and eye diseases, and designs healthy future with early personalized treatment.

Recent News

EDGC Recent News

Article

 A Korean genetic sequencing firm has taken a step towards the commercialization of its liquid biopsy technology, which aims at detecting early stage cancer with a simple blood test and suggesting optimized treatment.Eone Diagnomics Genome Center (EDGC) announced that it applied for a U.S. as well as an international patent under the PCT system for its DNA methylation analysis technology.The technology is based on a liquid biopsy, which is a cutting-edge technology that can be applied throughout the whole treatment cycle, from the early detection of cancer and monitoring of its recurrence and spread, to the provision of anticancer drugs tailored to each patient.For mass screenings aimed at the early detection of cancer, a small amount of blood is taken from a person in order to detect circulating tumor DNA (ctDNA), or DNA that originates from cancerous cells. In the case of early-stage cancer, however, ctDNA exists in an extremely small amount, making it very difficult to detect.Global liquid biopsy firms have thus been seeking to overcome this barrier. Recently, methylation analysis of the cancer genome has been in the spotlight as a technology that can solve this problem, but there hasn't been much progress made, due to the difficulty of its application in early-stage cancer, where only a tiny amount of ctDNA is present.EDGC says that it has solved the problem by extracting a specific methylation pattern in the cancer genome through a next generation sequencing (NGS) method and analysis consisting of an AI algorithm.The company says that the technology enables the analysis of more than tens of thousands of methylation markers, while guaranteeing high sensitivity in the analysis, even if there is an ultra-small amount of ctDNA.EDGC already obtained a patent in July for its technology, which selectively removes free adapters that affect the sensitivity of the analysis."Early-stage detection of cancer using liquid biopsies is the first step towards cancer treatment through precision medicine. The methylation-based technology we have developed has enabled us to get a head start in the global competition over the early detection of cancer," said Lee Sung-hoon, the chief technology officer (CTO) of EDGC. 

2021.10.12

Global Network

EONE-DIAGNOMICS GENOME CENTER

EDGC Promotion Video

No posts found.